ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.
An existing oral drug already used to treat lung cancer could help improve survival rates for bladder cancer patients, a new clinical trial by UK scientists has found. There are approximately 10,300 ...
Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...
The Phase III study was held in Chinese locations and the HER2-targeting ADC Aidixi is unlikely to launch in markets outside China.
An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
Nearly 84,000 Americans will receive a bladder cancer diagnosis this year, yet most people remain unaware of the early warning signs that could save their lives. This silent disease often masquerades ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback